Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S : announces CE-IVD approval for suPARnostic® TurbiLatex on the Siemens Healthineers Atellica® platform

06/04/2021 | 06:48am EDT

COMPANY ANNOUNCEMENT - No. 15-2021 - 04 June 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient outcomes and reduce healthcare costs, announces that it has completed the development and regulatory approval (CE-IVD in Europe) of its suPARnostic® TurbiLatex product for the Siemens Healthineers Atellica® platform.

The Atellica® platform is the most recent clinical chemistry and immunoassay system from Siemens Healthineers. The system has particular advantages since maintenance and inspections can be run while the system is operational, and the “down-time” is markedly reduced compared to previous systems. In addition, Atellica® is a fully automated system requiring no manual handling from the blood sampling until results are processed.

The approval of suPARnostic® TurbiLatex for the Atellica® system complements the previous approvals for the Abbott Architect™, Abbott Alinity™, the Roche Diagnostics cobas® systems, and the Siemens Healthineers ADVIA® Chemistry XPT system.

The suPARnostic® Turbilatex product is a pivotal element in ViroGates’ European expansion strategy, focusing on the acute care market.

CEO Jakob Knudsen says in a comment: ”We are excited to be able to offer suPARnostic® TurbiLatex on the Atellica® platform from Siemens Healthineers. We experience that Atellica® is capturing markets share, and we have potential customers who have been waiting to complete the validation for this platform. We look forward to implementing suPARnostic® TurbiLatex at these hospitals to support faster and better patient triage decisions to the benefit of patients, hospitals, and payers.”

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

  • Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

© Ritzau Denmark, source Ritzau English Regulatory Releases

Stocks mentioned in the article
ChangeLast1st jan.
SIEMENS HEALTHINEERS AG -0.22% 54.72 Delayed Quote.30.68%
VIROGATES A/S 6.19% 154.5 Delayed Quote.78.53%
All news about VIROGATES A/S
07/21VIROGATES A/S : SuPAR is a useful biomarker to investigate the link between stre..
PU
06/15VIROGATES A/S : SuPAR is a valuable tool for predicting the risk of developing s..
PU
06/11VIROGATES A/S : notification of transactions by persons discharging managerial r..
AQ
06/04VIROGATES A/S : announces CE-IVD approval for suPARnostic® TurbiLatex on the Sie..
AQ
06/03NEW STUDY : suPAR cut-offs for stratification of acute medical patients
PU
06/02VIROGATES A/S : General Hospital of Nikaia Agios Panteleimon
PU
06/02VIROGATES A/S : ED triage at Sismanoglio General Hospital
PU
05/28VIROGATES A/S : announces its first clinical routine customer in Italy
AQ
05/21VIROGATES A/S : announces a capital increase in connection with the exercise of ..
AQ
05/20PREPRINT PUBLISHED : suPAR guided early anakinra treatment for COVID-19
PU
More news
Financials
Sales 2020 5,35 M 0,85 M 0,85 M
Net income 2020 -18,7 M -2,96 M -2,96 M
Net cash 2020 33,5 M 5,30 M 5,30 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 461 M 73,0 M 72,9 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float 50,1%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Jörgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S78.53%88
EXACT SCIENCES CORPORATION-10.91%22 056
GUARDANT HEALTH, INC.-7.32%12 461
BGI GENOMICS CO., LTD.-20.59%7 539
INVITAE CORPORATION-32.07%6 884
ADAPTIVE BIOTECHNOLOGIES CORPORATION-36.23%5 670